Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.455 AUD | -1.09% | 0.00% | +31.88% |
05-17 | Capital One Initiates Immutep at Overweight Rating With $10 Price Target | MT |
05-15 | Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.88% | 375M | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Immutep Says US FDA Awarded Fast Track Designation for Proposed Treatment of First-Line Non-Small Cell Lung Cancer